Osiris Therapeutics, Inc. was founded in 1992 based on stem cell technology discovered by researchers at Case Western Reserve University led by Dr. Arnold Caplan. He recognized this technology had tremendous therapeutic potential.
Today, more than two decades after the journey began, Osiris continues to advance the science of cellular regenerative medicine to treat patients in need. Osiris Therapeutics, based in Columbia, Maryland, is the world leader in researching, developing and marketing regenerative medicine products. Having developed the world’s first approved stem cell drug, the company continues to advance its research and development in biotechnology by focusing on innovation in regenerative medicine – including bioengineering, stem cell research and viable tissue based products. Osiris has achieved commercial success with products in orthopaedics, sports medicine and wound care, including BIO4™, Cartiform® and Grafix®. Osiris, Grafix, and Cartiform are registered trademarks of Osiris Therapeutics, Inc. BIO4 is a trademark of Stryker Corporation (NYSE: SYK).
Key People at Osiris Therapeutics
Linda Palczuk
Philip R. Jacoby
Osiris Therapeutics Office Locations
Osiris Therapeutics Data and Metrics
Osiris Therapeutics Financial Metrics
Net income (FY, 2014) | (1.8 m) |
EBIT (FY, 2014) | 1.7 m |
Market capitalization (20-Jul-2017) | 235.7 m |
Closing share price (20-Jul-2017) | 6.8 |
Cash (31-Dec-2014) | 2.2 m |
| USD | FY, 2013 | FY, 2014 |
|---|---|---|
Operating expense total | 20.5 m | 45 m |
EBIT | (2.8 m) | 1.7 m |
Net Income | 41.6 m | (1.8 m) |
| USD | FY, 2013 | FY, 2014 |
|---|---|---|
Cash | 2.4 m | 2.2 m |
Accounts Receivable | 15.3 m | 10 m |
Inventories | 355 k | 650 k |
Current Assets | 84.1 m | 95.9 m |
PP&E | 1.9 m | 2.1 m |
Total Assets | 92.1 m | 98.1 m |
Accounts Payable | 4.8 m | 8.9 m |
Current Liabilities | 10.8 m | 10.6 m |
Additional Paid-in Capital | 282.7 m | 287.5 m |
Retained Earnings | (201.8 m) | (203.5 m) |
Total Equity | 80.9 m | 84 m |
Financial Leverage | 1.1 x | 1.2 x |
| USD | FY, 2013 | FY, 2014 |
|---|---|---|
Depreciation and Amortization | 587 k | 940 k |
Accounts Receivable | (4.7 m) | (18 m) |
Inventories | (651 k) | (9 m) |
Accounts Payable | (2.8 m) | (57 k) |
Cash From Operating Activities | (13.3 m) | (3.1 m) |
Purchases of PP&E | (528 k) | (1.1 m) |
Cash From Investing Activities | 11.6 m | 1.1 m |
Cash From Financing Activities | 2.2 m | 1.9 m |
Income Taxes Paid | 539 k | 619 k |
| Y, 2014 | |
|---|---|
Financial Leverage | 1.2 x |
